StockData
Charles River Laboratories International, Inc. logo

Charles River Laboratories International, Inc. (CRL) stock

CRLNYSEServices-Commercial Physical & Biological ResearchFiscal year ends December 27
Financials through Q2 FY2026, quarter ended Jun 27, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30225% above fair value
$333.25+1.09 (+0.33%)

Close on Nov 18, 2026Market cap $15.91BP/E –Yield –

Charles River Laboratories International operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Charles River Laboratories International's operating cash flow for the twelve months ending Jun 27, 2026 was $582.15M, down 26.1% year over year. For fiscal 2025 it was $737.65M, up 0.4% from the year before. Over ten years it grew 9.2% a year on average. The highest annual figure on record is $760.80M in fiscal 2021.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 27, 2025$737.65M+0.4%
FY2024Dec 28, 2024$734.58M+7.4%
FY2023Dec 30, 2023$683.90M+10.4%
FY2022Dec 31, 2022$619.64M-18.6%
FY2021Dec 25, 2021$760.80M+39.2%
FY2020Dec 26, 2020$546.58M+13.6%
FY2019Dec 28, 2019$480.94M+9.0%
FY2018Dec 29, 2018$441.14M+38.7%
FY2017Dec 30, 2017$318.07M+0.4%
FY2016Dec 31, 2016$316.90M+3.3%
FY2015Dec 26, 2015$306.83M+21.7%
FY2014Dec 27, 2014$252.13M+20.6%
FY2013Dec 28, 2013$209.05M+0.5%
FY2012Dec 29, 2012$208.01M+0.6%
FY2011Dec 31, 2011$206.84M+22.9%
FY2010Dec 25, 2010$168.24M-22.0%
FY2009Dec 26, 2009$215.58M-21.8%
FY2008Dec 27, 2008$275.57M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 27, 2026$179.73M-12.2%
Q1 FY2026Mar 28, 2026$41.08M-76.1%
Q4 FY2025Dec 27, 2025$147.52M-7.4%
Q3 FY2025Sep 27, 2025$213.83M-15.1%
Q2 FY2025Jun 28, 2025$204.60M+5.7%
Q1 FY2025Mar 29, 2025$171.70M+32.2%
Q4 FY2024Dec 28, 2024$159.36M-27.9%
Q3 FY2024Sep 28, 2024$251.79M+22.6%
Q2 FY2024Jun 29, 2024$193.54M+30.7%
Q1 FY2024Mar 30, 2024$129.89M+18.7%
Q4 FY2023Dec 30, 2023$220.94M-5.9%
Q3 FY2023Sep 30, 2023$205.45M+54.7%
Q2 FY2023Jul 1, 2023$148.12M-0.9%
Q1 FY2023Apr 1, 2023$109.38M+6.6%
Q4 FY2022Dec 31, 2022$234.76M+2.4%
Q3 FY2022Sep 24, 2022$132.78M-24.0%
Q2 FY2022Jun 25, 2022$149.47M-19.9%
Q1 FY2022Mar 26, 2022$102.63M-39.7%
Q4 FY2021Dec 25, 2021$229.26M+65.7%
Q3 FY2021Sep 25, 2021$174.72M-1.5%
Q2 FY2021Jun 26, 2021$186.59M+15.0%
Q1 FY2021Mar 27, 2021$170.23M+148.2%
Q4 FY2020Dec 26, 2020$138.38M-23.4%
Q3 FY2020Sep 26, 2020$177.30M+13.8%
Q2 FY2020Jun 27, 2020$162.31M+25.3%
Q1 FY2020Mar 28, 2020$68.59M+361.6%
Q4 FY2019Dec 28, 2019$180.68M+29.1%
Q3 FY2019Sep 28, 2019$155.85M+32.9%
Q2 FY2019Jun 29, 2019$129.55M+4.6%
Q1 FY2019Mar 30, 2019$14.86M-75.3%
Q4 FY2018Dec 29, 2018$139.97M+12.7%
Q3 FY2018Sep 29, 2018$117.24M+97.1%
Q2 FY2018Jun 30, 2018$123.87M+23.5%
Q1 FY2018Mar 31, 2018$60.05M+76.5%
Q4 FY2017Dec 30, 2017$124.24M+4.7%
Q3 FY2017Sep 30, 2017$59.49M-17.7%
Q2 FY2017Jul 1, 2017$100.32M–
Q1 FY2017Apr 1, 2017$34.03M–
Q4 FY2016Dec 31, 2016$118.65M–
Q3 FY2016Sep 24, 2016$72.30M–

More Charles River Laboratories International figures

See a number that looks wrong?